Ultragenyx Announces Positive CHMP Opinion for Mepsevii(TM) (vestronidase alfa) For the Treatment of Mucopolysaccharidosis VII

NOVATO, Calif., June 29, 2018 -- (Healthcare Sales & Marketing Network) -- Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) today announced that the Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medicines Agenc... Biopharmaceuticals, Regulatory Ultragenyx Pharmaceutical, Mepsevii, vestronidase alfa, Mucopolysaccharidosis
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news